<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Apheresis has been effective as rescue therapy in patients with severe, therapy-resistant, <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="1" pm="."><plain>Its benefit in patients with less severe but therapy-resistant SLE is not known </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="34674">Dextran sulfate</z:chebi> apheresis was applied as a rescue therapy for therapy-resistant vasculitic <z:mp ids='MP_0001212'>skin lesions</z:mp> in a 30 year old female patient with a 9 year history of SLE in combination with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and <z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud's phenomenon</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Partial remission was achieved after 9 immunoadsorption sessions, as documented by marked improvement of <z:mp ids='MP_0001212'>skin lesions</z:mp> and an increase of capillary density in the nailfold area </plain></SENT>
<SENT sid="4" pm="."><plain>Further improvement was noted with maintenance therapy using <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="34674">Dextran sulfate</z:chebi> apheresis can be applied safely in patients with moderate therapy-resistant SLE disease activity when severe <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> and cytotoxic adverse effects should be avoided </plain></SENT>
</text></document>